BridgeBio Oncology Therapies Posts 65% ORR in NSCLC and Extends Runway to 2028
BBOT•BridgeBio Oncology Therapeutics reported its BBO-8520 KRAS G12C inhibitor achieved a 65% objective response rate and 68% six-month progression-free survival in NSCLC. The company noted a 56% tumor reduction in pancreatic cancer with its pan-KRAS inhibitor BBO-11818 and expects cash runway into 2028.
1. Financial Position & Runway
As of March 31, 2026, BBOT held cash, cash equivalents and marketable securities sufficient to fund operations into 2028.
2. BBO-8520 Clinical Data
The KRAS G12C inhibitor BBO-8520 showed a 65% objective response rate and 68% six-month progression-free survival as monotherapy in NSCLC; combination trials with pembrolizumab demonstrated promising efficacy and a differentiated liver toxicity profile, with updated data expected in the second half of 2026.
3. BBO-11818 & BBO-10203 Updates
The pan-KRAS inhibitor BBO-11818 achieved a 56% tumor reduction in pancreatic ductal adenocarcinoma with no dose-limiting toxicities, supported by a peer-reviewed publication; the RAS–PI3Kα inhibitor BBO-10203 confirmed full target engagement without hyperglycemia and demonstrated clinical benefit in colorectal and hormone receptor–positive breast cancer, with combination studies planned for later in 2026.
4. Corporate Leadership Changes
Pedro J. Beltran, PhD, assumed the role of CEO and Idan Elmelech became COO in April 2026, while Neil Kumar, PhD, took on Executive Chairman duties and Eli Wallace, PhD, transitioned to Senior Adviser; Peter F. Lebowitz, MD, PhD, also joined the Board of Directors.
